PR与UPA在乳腺癌中的表达及其临床意义  

Expression and clinical significance of PR and UPA in breast cancer

作　　者：冯丹[1] 薄爱华[1] 张彦[1] 吉艳荣[1] 

机构地区：[1]河北北方学院,河北张家口075029

出　　处：《现代肿瘤医学》2010年第3期497-498,共2页Journal of Modern Oncology

摘　　要：目的:研究乳腺癌组织中孕激素受体(PR)和尿激酶型纤溶酶原激活物(UPA)表达的相关性及临床意义。方法:采用免疫组织化学SABC法,检测70例乳腺癌组织中PR及UPA的表达情况。结果:乳腺癌中PR的阳性率为61.43%(43/70),UPA的阳性率为64.29%(45/70),二者的表达成低度相关,r=0.083。PR在无淋巴结转移组明显高于有淋巴结转移组(P<0.05),UPA阳性率在有淋巴结转移组和浸润型乳癌组明显高于无淋巴结转移组和非浸润组(P<0.05)。结论:PR和UPA在乳腺癌中表达与淋巴结转移有相关性。检测PR和UPA对临床选择治疗方法有指导意义。Objective：To study expression and clinical significance of PR and UPA in breast cancer. Methods： SABC immunohistochemical stain was used to detect the expression of PR and UPA in 70 cases of breast cancer. Results：The positive rates of PR and UPA were 61.43% （43/70） and 64.29% （45/70） in breast cancer respectively. PR had a low relation with UPA in breast cancer （ r = 0. 083 ）. The positive rates of PR in non - lymphmetastasis group was higher than that in lymphmetastasis （ P 〈 0.05 ）, the positive rates of UPA in lymphmetastasis group and in- filtration cancer group were higher than that of non - lymphmetastasis group and non - infiltration group（ P 〈 0. 05 ）. Conclusion：The expression of PR and UPA had relation with breast cancer metastasis.

关 键 词：乳腺癌 孕激素受体 尿激酶型纤溶酶原激活物 免疫组织化学 

分 类 号：R730.3[医药卫生—肿瘤]